Compare BETR & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BETR | ELDN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.6M | 219.4M |
| IPO Year | 2021 | 2014 |
| Metric | BETR | ELDN |
|---|---|---|
| Price | $15.27 | $2.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $24.00 | $9.00 |
| AVG Volume (30 Days) | 849.4K | ★ 910.2K |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.88 | ★ 30.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $164,872,000.00 | N/A |
| Revenue This Year | $13.39 | N/A |
| Revenue Next Year | $23.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 51.97 | N/A |
| 52 Week Low | $7.51 | $1.35 |
| 52 Week High | $55.75 | $4.49 |
| Indicator | BETR | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 45.92 | 38.28 |
| Support Level | $10.45 | N/A |
| Resistance Level | $31.07 | $3.19 |
| Average True Range (ATR) | 2.39 | 0.28 |
| MACD | -0.68 | -0.03 |
| Stochastic Oscillator | 3.48 | 3.05 |
Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.